▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #133 by analyst upside · 2026-11-12
CATX
Perspective Therapeutics, Inc.
Healthcare · Market Cap $100M · P/E 0x
ANALYST PRICE TARGET
+1103.2%
implied upside to consensus target
Current Price $0.83
Consensus Target $9.93
Bull Target $15.0
Bear Target $4.0
Analysts Covering 14
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
11
Hold
2
Sell
0
52-Week Low $0.78
52-Week High $6.16
YTD Return -70.3%
FUNDAMENTALS
Market Cap $100M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.31
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $0M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.78
52-Week High $6.16
Current Price $0.83
Bear Target $4.0
Bull Target $15.0
● Now $0.83 ● Target $9.93
TRADING DATA
Avg Volume 2.5M
YTD Return -70.3%
Analyst Count 14
Consensus Buy
Upside to Target +1103.2%
Last Updated 2026-11-12

ANALYST SUMMARY

Perspective Therapeutics, Inc. (CATX) is currently trading at $0.83 with a Wall Street consensus price target of $9.93, implying potential upside of 1103.2% over the next 12 months. 14 analysts currently cover CATX, with a consensus rating of Buy - 86% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $15.0, while the most cautious has a target of $4.0.

CATX operates in the Healthcare sector with a market capitalisation of $100M. The stock is down 70.3% year-to-date and is currently trading near the lower end of its 52-week range of $0.78 – $6.16.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

DWTX +1086.4%
Dogwood Therapeutics, Inc.
$45M · P/E 0.1x · Strong Buy
VXRT +800.9%
Vaxart, Inc.
$90M · P/E 2.8x · Buy
ETST +1036.4%
Earth Science Tech, Inc.
$25M · P/E 8.8x · Hold
PALI +660.7%
Palisade Bio, Inc.
$204M · P/E 1.9x · Buy
NCEL +721.4%
NewcelX Ltd.
$16M · P/E 5.6x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for CATX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

RBC Capital ↓ Downgrade
Outperform → Sector Perform 2026-10-26 Building track record
BTIG reit
Buy → Buy 2026-10-07 38% win rate (8 calls)
William Blair ● Initiated
Outperform 2026-09-18 44% win rate (9 calls)
Wedbush reit
Outperform → Outperform 2026-09-15 Building track record
BMO Capital ● Initiated
Outperform 2026-08-19 Building track record
B of A Securities - Reiterated
Neutral → Neutral 2026-08-14 Building track record
Piper Sandler - Reiterated
Overweight → Overweight 2026-08-11 14% win rate (7 calls)
Wedbush reit
Outperform → Outperform 2026-05-05 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
43
out of 100
Coverage depth
21/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →